To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

Completed · Phase 1 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

The purpose of this study is to investigate the safety and tolerability of AZD5658 following ascending single oral doses in Type 2 Diabetics. It will also estimate the maximum tolerated dose.

Key facts

Study ID

NCT01176097

Run by

AstraZeneca

People needed

24

Starts

2010-07-01

Expected to finish

2011-02-01

Last updated by the study team

2012-02-02

Who can join

Age: 20 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be of non-childbearing potential.
• Body mass index between greater than or equal to 19 and less than or equal to 40 kg/m2
• Patients with confirmed Type 2 Diabetes diagnosis for at least 1 year and treated with Metformin

You may not qualify if…

• Clinically significant illness or clinically relevant trauma within 2 weeks before the first administration of the IP
• Participation in another clinical study during the last 30 days prior to enrollment
• Significant cardiovascular event within the last 6 months prior to enrollment

Where it is running

• Research Site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.